We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+21.05%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$340M
AUM Growth
-$154M
(-31%)
Cap. Flow
-$77.8M
Cap. Flow % of AUM
Cap. Flow %
-22.9%
Top 10 Holdings %
Top 10 Hldgs %
53.86%
Holding
71
New
18
Increased
9
Reduced
13
Closed
25
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$20.8M |
| 2 |
bluebird bio
BLUE
|
+$18.5M |
| 3 |
PTC Therapeutics
PTCT
|
+$14.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$11M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$8.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$20.2M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$17.5M |
| 3 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$16.7M |
| 4 |
Viatris
VTRS
|
+$14.4M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.66% |
| 2 | Miscellaneous | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $29.6M | 8.71% |
1,250,000
-600,000
| -32% | -$12.1M |
2016 Q2
8 quarters
|
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $24.6M | 7.25% |
500,000
+237,500
| +90% | +$8.97M |
2017 Q4
2 quarters
|
|
3
Sarepta Therapeutics
SRPT
$1.72B
| $23.1M | 6.81% |
175,000
-60,000
| -26% | -$5.66M |
2018 Q1
1 quarter
|
|
|
4
PTC Therapeutics
PTCT
$5.3B
| $22.8M | 6.7% |
675,000
+475,000
| +238% | +$14.8M |
2018 Q1
1 quarter
|
|
|
5
Alnylam Pharmaceuticals
ALNY
$22.1B
| $20.7M | 6.09% |
+210,000
| New | +$20.8M |
2018 Q2
0 quarters
|
|
|
6
DELISTED
bluebird bio
BLUE
| $16.5M | 4.85% |
+8,106
| New | +$18.5M |
2018 Q2
0 quarters
|
|
7
argenx
ARGX
$60.4B
| $12.4M | 3.66% |
150,000
| – | – |
2017 Q2
4 quarters
|
|
8
Ascendis Pharma A/S
ASND
$18.1B
| $11.6M | 3.43% |
175,000
+35,000
| +25% | +$2.3M |
2017 Q3
3 quarters
|
|
|
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $10.9M | 3.22% |
+242,000
| New | +$11M |
2018 Q2
0 quarters
|
|
10
DELISTED
Mersana Therapeutics
MRSN
| $10.7M | 3.15% |
24,000
+12,870
| +116% | +$5.65M |
2018 Q1
1 quarter
|
|
11
Arrowhead Research
ARWR
$6.75B
| $9.5M | 2.8% |
700,000
-100,000
| -13% | -$935K |
2018 Q1
1 quarter
|
|
12
Assembly Biosciences
ASMB
$430M
| $9.21M | 2.71% |
19,583
+7,083
| +57% | +$3.75M |
2018 Q1
1 quarter
|
|
13
Exelixis
EXEL
$16.8B
| $8.61M | 2.53% |
+400,000
| New | +$8.27M |
2018 Q2
0 quarters
|
|
14
Acadia Pharmaceuticals
ACAD
$3.24B
| $8.17M | 2.4% |
535,000
+135,000
| +34% | +$2.41M |
2018 Q1
1 quarter
|
|
|
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.08M | 2.38% |
660,000
-290,000
| -31% | -$3.64M |
2017 Q4
2 quarters
|
|
|
ADMS
16
DELISTED
Adamas Pharmaceuticals
ADMS
| $7.62M | 2.24% |
295,000
-30,000
| -9% | -$831K |
2018 Q1
1 quarter
|
|
|
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
| $7.58M | 2.23% |
1,900,000
+300,000
| +19% | +$1.17M |
2017 Q3
3 quarters
|
|
|
ECYT
18
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $6.9M | 2.03% |
500,000
-1,700,000
| -77% | -$20.2M |
2018 Q1
1 quarter
|
|
19
Rocket Pharmaceuticals
RCKT
$252M
| $6.87M | 2.02% |
350,000
-500,000
| -59% | -$9.46M |
2017 Q4
2 quarters
|
|
20
Madrigal Pharmaceuticals
MDGL
$9.9B
| $6.57M | 1.93% |
+23,500
| New | +$4.13M |
2018 Q2
0 quarters
|
|
21
Tectonic Therapeutic
TECX
$413M
| $6.57M | 1.93% |
+19,167
| New | +$6.91M |
2018 Q2
0 quarters
|
|
22
Crescent Biopharma
CBIO
$526M
| $6.45M | 1.9% |
4,000
+1,500
| +60% | +$2.58M |
2018 Q1
1 quarter
|
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $6.23M | 1.83% |
900,000
| – | – |
2017 Q2
4 quarters
|
|
|
OBSV
24
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $6.06M | 1.78% |
400,000
| – | – |
2017 Q4
2 quarters
|
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| $5.56M | 1.64% |
+186,019
| New | +$5.2M |
2018 Q2
0 quarters
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Ghost Tree Capital held 71 positions worth $340M, down 31% from $494M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Ghost Tree Capital withdrew a net $77.8M in Q2 2018, closing 25 positions and reducing 13 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $17.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 75% a quarter earlier, followed by Miscellaneous.
Against the trend, Ghost Tree Capital opened a new position in Alnylam Pharmaceuticals worth $20.7M.
- Ghost Tree Capital's largest Q2 2018 buy was Alnylam Pharmaceuticals: 210,000 shares worth $20.7M.
- Ghost Tree Capital added most to PTC Therapeutics in Q2 2018, an estimated $14.8M increase.
- Ghost Tree Capital's biggest Q2 2018 reduction was Endocyte, Inc. Common Stock, cutting an estimated $20.2M.
- Ghost Tree Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018, selling an estimated $17.5M.
- Ghost Tree Capital's ten largest holdings make up 54% of its $340M portfolio in Q2 2018.
- Ghost Tree Capital opened 18 new positions and closed 25 in Q2 2018.
- Ghost Tree Capital's portfolio value fell 31% quarter-over-quarter to $340M.
Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.